SCHEMBL5690995

SCHEMBL5690995

COC(=O)Cc1cc(O)c(N)c(OC)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 1/20 0.54
GAA P10253 5/20 0.54
ALDH1A1 P00352 3/20 0.54
GFER P55789 1/20 0.54
TSHR P16473 3/20 0.44
NFKB1 P19838 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
ALOX5 P09917 2/20 0.43
OR51E2 Q9H255 1/20 0.41
KMT2A Q03164 3/20 0.40
CYP4F2 P78329 1/20 0.40
CYP4A11 Q02928 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
EP300 Q09472 1/20 0.39
MAPK1 P28482 1/20 0.39
TAAR1 Q96RJ0 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3456779 0.81 HSP90AB1 (0.63) HSP90AB1GAAALDH1A1GFERTSHR
SCHEMBL11215998 0.81 ALDH1A1 (0.58) HSP90AB1GAAALDH1A1GFERTSHR
SCHEMBL7131019 0.78 KMT2A (0.58) HSP90AB1GAAALDH1A1TDP1KMT2A
SCHEMBL4545435 0.78 HSP90AB1 (0.63) HSP90AB1GAAALDH1A1GFERTSHR
SCHEMBL8204330 0.77 HSP90AB1 (0.68) HSP90AB1GAAALDH1A1GFERTSHR
SCHEMBL1751797 0.77 GAA (0.73) GAAALDH1A1GFERTSHRNFKB1
SCHEMBL1011093 0.77 GAA (0.73) HSP90AB1GAAALDH1A1GFERTSHR
SCHEMBL30128009 0.77 GAA (0.73) GAAALDH1A1GFERTSHRNFKB1
SCHEMBL5690672 0.76 HSP90AB1 (0.49) HSP90AB1GAAALDH1A1GFERTSHR
SCHEMBL5701107 0.75 ALDH1A1 (0.64) HSP90AB1GAAALDH1A1GFERTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1153017-B1 BICYCLIC COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR LIGANDS AVENTIS PHARMA LTD (GB) 2006-05-03 EP disclosed
US-6593354-B2 Amide substituted benzimidazole or benzoxazole; regulating the interaction of vascular cell adhesion molecule-1 and fibronectin with the integrin vascular cell adhesion molecule very late antigen-4 AVENTIS PHARMA LIMITED (GB) 2003-07-15 US disclosed
US-20020137782-A1 Substituted bicyclic compounds AVENTIS PHARMA LIMITED (GB) 2002-09-26 US disclosed
EP-1153017-A1 BICYCLIC COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR LIGANDS Aventis Pharma Limited (GB) 2001-11-14 EP disclosed
WO-2000049005-A1 BICYCLIC COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR LIGANDS AVENTIS PHARMA LIMITED (GB) 2000-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137782-A1 Substituted bicyclic compounds ITGA1, VCAM1, ITGB1 HSP90AB1 3328/4885GAA 3668/4885ALDH1A1 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.